Journal article
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
- Abstract:
- Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2) inhibitor therapies improve blood glucose control and also reduce cardiovascular events and heart failure hospitalisations in patients with type 2 diabetes. Intriguingly, such clinical benefits have also been seen in patients with heart failure in the absence of type 2 diabetes although the underlying mechanisms are not clearly understood. Potential pathways include improved glycaemic control, diuresis, weight reduction and reduction in blood pressure, but none fully explain the observed improvements in clinical outcomes. More recently, novel mechanisms have been proposed to explain these benefits that include improved cardiomyocyte calcium handling, enhanced myocardial energetics, induced autophagy and reduced epicardial fat. We provide an up-to-date review of cardiac-specific SGLT2 inhibitor-mediated mechanisms and highlight studies currently underway investigating some of the proposed mechanisms of action in cardiovascular health and disease.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.4MB, Terms of use)
-
- Publisher copy:
- 10.1136/heartjnl-2020-318060
- Publication website:
- https://www.research.ed.ac.uk/files/217981001/1032.full.pdf
Authors
+ Wellcome Trust
More from this funder
- Funder identifier:
- 10.13039/100004440
- Grant:
- DEN is the recipient of a Wellcome Trust Senior In
+ British Heart Foundation
More from this funder
- Funder identifier:
- 10.13039/501100000274
- Grant:
- DEN is supported by the BHF (CH/09/002, RG/16/10/3
+ Medical Research Council
More from this funder
- Funder identifier:
- 10.13039/501100000265
- Grant:
- TS is supported by MRC CRTF (MR/T029153/1)
+ AstraZeneca
More from this funder
- Funder identifier:
- 10.13039/100004325
- Grant:
- SJ is also supported by an investigator initiated
+ British Heart Foundation, Medical Research Council, Wellcome Trust, AstraZeneca
More from this funder
- Grant:
- The authors are supported by British Heart Foundation [SJ, RE/18/5/3 and FS/CRTF/20/24087; TS, RE/18/5/3; DEN, CH/09/002, RG/18/5/3), Medical Research Council (TS, MR/T029153/1), Wellcome Trust (DEN, WT103782AIA) and an investigator initiated award from AstraZeneca (SJ, SER-19-20118)]
- Publisher:
- BMJ Publishing Group
- Journal:
- Heart More from this journal
- Volume:
- 107
- Issue:
- 13
- Pages:
- 1032-1038
- Publication date:
- 2021-02-26
- DOI:
- EISSN:
-
1468-201X
- ISSN:
-
1355-6037
- Language:
-
English
- Keywords:
- Pubs id:
-
1504633
- Local pid:
-
pubs:1504633
- Source identifiers:
-
W3131396654
- Deposit date:
-
2026-05-12
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2021
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record